| Identification | Back Directory | [Name]
AG-012986 | [CAS]
486414-35-1 | [Synonyms]
AG-012986 BENZAMIDE, 4-[[4-AMINO-5-(2,6-DIFLUOROBENZOYL)-2-THIAZOLYL]AMINO]-N-[(1R)-2-(DIMETHYLAMINO)-1-METHYLETHYL]- | [Molecular Formula]
C22H23F2N5O2S | [MDL Number]
MFCD11100260 | [MOL File]
486414-35-1.mol | [Molecular Weight]
459.51 |
| Hazard Information | Back Directory | [Uses]
AG-012986 is a multitargeted CDK inhibitor. AG-012986 is active against CDK1/2/4/6/5/9, with Kis of 9.2 nM (CDK4/cyclin), 94 nM (CDK2/cyclin A), and 44 nM (CDK1/cyclin B), IC50s of 4 nM (CDK9/cyclin T) and 22 nM (CDK5/p35). AG-012986 has antiproliferative activities against cancer cells. AG-012986 induces cell cycle arrest, and apoptosis[1]. | [IC 50]
Cdk1/cyclin B: 44 nM (Ki); cdk2/cyclin A: 94 nM (Ki); CDK4: 9.2 nM (Ki); CDK5/p35: 22 nM (IC50); CDK9/Cyclin T: 4 nM (IC50) | [References]
[1] Zhang C, et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol Cancer Ther. 2008 Apr;7(4):818-28. DOI:10.1158/1535-7163.MCT-07-0440 |
|
|